drugset / Trial / NCT01454063

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063

Phase 3 Completed 405 enrolled Omeros Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of OMS302 (the study drug) for maintaining intraoperative mydriasis in individuals undergoing Intraocular Lens Replacement (ILR) surgery.

Timeline

Start
2011-09
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject OMS302 Unknown Other

Indications

No indication recorded.